David Nachbaur

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Sabine Käyser, Konstanze Döhner, Jürgen Krauter et al. · Blood · 2010 · 479 citations

<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group

Verena I. Gaidzik, Lars Bullinger, Richard F. Schlenk et al. · Journal of Clinical Oncology · 2011 · 449 citations · Full text

Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation

Richard F. Schlenk, Sabine Käyser, Lars Bullinger et al. · Blood · 2014 · 394 citations · Full text

Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

Jan Krönke, Richard F. Schlenk, Kai‐Ole Jensen et al. · Journal of Clinical Oncology · 2011 · 388 citations · Full text

Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer

Brigitte Eibl, H Schwaighofer, David Nachbaur et al. · Blood · 1996 · 269 citations · Full text